Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HCV Therapeutic Vaccine
- Development stage
- Preclinical
- Lead developer
- Auro Vaccines
- Modality
- DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Viral Vector Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
**HCV Therapeutic Vaccine** is Auro Vaccines' investigational pan-genotypic therapeutic hepatitis C virus vaccine program for chronic hepatitis C. It uses the PBS Vax™ heterologous prime-boost approach: a GeneVax™ DNA plasmid vaccine, co-administered with GeneVax IL-12™ and delivered by electroporation, primes cellular immunity; a VesiculoVax™ viral-vector boost is intended to expand durable HCV-specific CD4+ and CD8+ T-cell responses. The candidate is designed for use alongside antiviral drug therapy and targets all HCV genotypes. Auro Vaccines reports robust, broad, high-quality immune responses in non-human primates with National Cancer Institute support; further development is on hold and the program is available for out-licensing or co-development. ([aurovaccines.com](https://aurovaccines.com/pipeline/pbs-vax-therapeutic-vaccines/))
- Other names
- hepatitis C virus therapeutic vaccinepan-genotypic HCV vaccine
Beyond the preview
Go deeper on HCV Therapeutic Vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HCV Therapeutic Vaccine.